GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taro Pharmaceutical Industries Ltd (NYSE:TARO) » Definitions » Current Accrued Expense

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Current Accrued Expense : $0.0 Mil (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is Taro Pharmaceutical Industries Current Accrued Expense?

Taro Pharmaceutical Industries's Current Accrued Expense for the quarter that ended in Dec. 2023 was $0.0 Mil.

Taro Pharmaceutical Industries's annual Current Accrued Expense increased from Mar. 2021 ($40.7 Mil) to Mar. 2022 ($49.0 Mil) but then declined from Mar. 2022 ($49.0 Mil) to Mar. 2023 ($47.0 Mil).


Taro Pharmaceutical Industries Current Accrued Expense Historical Data

The historical data trend for Taro Pharmaceutical Industries's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taro Pharmaceutical Industries Current Accrued Expense Chart

Taro Pharmaceutical Industries Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.37 35.81 40.74 49.04 47.01

Taro Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 47.01 - - -

Taro Pharmaceutical Industries Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Taro Pharmaceutical Industries Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Taro Pharmaceutical Industries's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Business Description

Traded in Other Exchanges
Address
14 Hakitor Street, P.O. Box 10347, Haifa Bay, Haifa, ISR, 2624761
Taro Pharmaceutical Industries Ltd produces, researches, develops, and markets pharmaceutical products. Its primary focus includes semi-solid formulations, such as creams and ointments, and other dosage forms such as liquids, capsules, and tablets. The company is engaged in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Israel, and Other Countries.
Executives
Sun Pharma Global Inc 10 percent owner
Sun Pharmaceutical Industries Ltd 10 percent owner, other: Affiliated Party 17/B, MAHAL INDUSTRIAL ESTATE, MAHAKALI CAVES ROAD, ANDEHERI (EAST) K7 400 093
Alkaloida Chemical Co Exclusive Group Ltd. 10 percent owner KABAY JANOS UT 29., TISZAVASVARI K5 4440
Franklin Resources Inc 10 percent owner FRANKLIN RESOURCES INC, ONE FRANKLIN PARKWAY, SAN MATEO CA 94403

Taro Pharmaceutical Industries (Taro Pharmaceutical Industries) Headlines

From GuruFocus

Taro Completes Acquisition of Alchemee

By Business Wire Business Wire 03-01-2022

Taro to Announce Full Year Results on May 19, 2021

By Business Wire Business Wire 05-12-2021

Taro to Release Second Quarter Results on October 27, 2022

By Business Wire Business Wire 10-24-2022

Taro Achieves Global Resolution of DOJ Antitrust Investigations

By Business Wire Business Wire 07-24-2020

Taro to Announce Third Quarter Results on January 27, 2022

By Business Wire Business Wire 01-21-2022

Taro to Announce First Quarter Results on July 27, 2021

By Business Wire Business Wire 07-21-2021